ET
REGN icon

Entropy Technologies’s Regeneron Pharmaceuticals REGN Stock Holding History

Entropy Technologies’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.99M Buy
9,606
+6,853
+249% +$4.66M 0.24% 119
2026
Q1 		$2.13M Buy
2,753
+1,747
+174% +$1.34M 0.1% 273
2025
Q4 		$777K Buy
+1,006
New +$683K 0.04% 448
2025
Q3 		– Sell
-7,196
Closed -$3.78M – 1053
2025
Q2 		$3.78M Sell
7,196
-1,894
-21% -$1.06M 0.3% 87
2025
Q1 		$5.77M Buy
9,090
+3,790
+72% +$2.61M 0.56% 35
2024
Q4 		$3.78M Buy
5,300
+4,900
+1,225% +$4.11M 0.39% 60
2024
Q3 		$420K Buy
+400
New +$445K 0.04% 481

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Entropy Technologies's REGN Position: Q2 2026 in Review

Entropy Technologies increased its Regeneron Pharmaceuticals (REGN) stake by 249% in Q2 2026, buying an estimated $4.66M and bringing the position to 9,606 shares worth $5.99M. The position accounts for 0.24% of the portfolio, ranked #119.

Entropy Technologies first reported a position in REGN in Q3 2024 and has held it in 7 quarters since. 1,335 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Entropy Technologies held 9,606 shares of Regeneron Pharmaceuticals worth $5.99M as of Q2 2026.
  • Entropy Technologies bought 6,853 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $4.66M.
  • Regeneron Pharmaceuticals made up 0.24% of Entropy Technologies's portfolio in Q2 2026, its #119 holding.
  • Entropy Technologies first reported a position in Regeneron Pharmaceuticals in Q3 2024 and has held it in 7 quarters since.
  • 1,335 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Entropy Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.